EGFR and pancreatic neoplasm: Wei et al. reported that the limited effect of AZD8055 as an ATP-competitive inhibitor of mTOR in pancreatic cancer cells was partly due to FOXO transcription factor–mediated upregulation of EGFR and its reactivation of Akt activity.